AveXis is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate, AVXS-101, is a proprietary gene therapy currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and SMA Types 2 and 3.

Acquired by Novartis in 2018, AveXis continues on its commitment to transform the lives of people devastated by rare and life threatening neurological diseases such as SMA, Rett syndrome and genetic ALS.

Our first meeting

We first met Brian in 2014. He and two others were trying to develop a novel gene-based therapy for neurodegenerative and neurodevelopmental disorders but did not have enough capital to fund the clinical trials. PBM team believed in the science behind Brian’s work and provided him with the first institutional funding. Our team joined the Company to let Brian do what does best and continue his research efforts while we ran day-to-day operations including overseeing finance, scaling up of CMC and navigating regulatory pathways.

We then helped to find the management team before the Company brought in crossover investors prior to its IPO in 2016.


Founded 2010
Partnered 2014
IPO 2016
Acquired 2018